Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch

Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger. That sounds like an easy valuation story until the profit figures enter the picture. Bristol Myers reported a 40% rise in second-quarter adjusted earnings per share, while Pfizer’s adjusted earnings were virtually unchanged. But those […]